Ally Bridge Group led a $120m funding round in Rapid Micro Biosystems, a provider of automated microbial detection technology for biopharmaceutical manufacturing. "We expect to see strong adoption of the company’s products, as increasing numbers of biopharmaceutical companies seek to take advantage of leading-edge technologies to support manufacturing speed and capacity improvements, as well as ensuring quality to satisfy increasingly stringent regulatory requirements," Frank Yu, Ally Bridge Group Founder, CEO and CIO.